FDA flags liver risks for AbbVie, Merck, Gilead hep C meds by Eric Sagonowsky Thursday, August 29, 2019 The FDA is tracking rare cases of liver damage and even death, mostly in patients who shouldn't have been taking the drugs in the first place.
Keytruda sales stoke Merck's Q1, but where's the future growth? by Arlene Weintraub Tuesday, May 1, 2018 Merck's Keytruda ginned up $1.46 billion in the first quarter, but analysts grilled CEO Ken Frazier about his plans to deliver new backup.
The #FierceMadness Final Four is set by Beth Snyder Bulik Wednesday, March 28, 2018 We're down to four, folks. The #FierceMadness Final Four field is set after an Elite Eight that featured both blowouts and close calls.
Gilead wins reversal of $2.54B verdict in Merck hep C case by Eric Sagonowsky Tuesday, February 20, 2018 The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead.
Merck to high-risk military veterans: Get a hep C education by Carly Helfand Monday, October 16, 2017 Veterans are far more likely to have hepatitis C, and Merck—which makes the antiviral therapy Zepatier—wants to make sure they know that.
Gilead nabs Chinese nod for Sovaldi, eyeing a 10M hep C base by Angus Liu Monday, September 25, 2017 Gilead Sciences has received approval for Sovaldi from China's FDA, gaining a foothold in the world's largest hepatitis C market.
Maryland team lands $6M from NIH to fund novel HCV vaccine by Angus Liu Tuesday, June 13, 2017 Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.
6. Kenneth Frazier by Tracy Staton Merck & Co. CEO Ken Frazier ostensibly got a 2.5% bump to his base salary that took it to $1.53 million, but also a $3 million decline in overall compensation to $21.78 million.
Gilead CEO touts new M&A scout amid clamor for deals by Eric Sagonowsky Wednesday, May 3, 2017 Armed with a revamped deal-scouting team, Gilead is eyeing oncology—and it isn't fazed by turbulence in Washington, CEO John Milligan said on Tuesday.
Merck’s Frazier gets his first salary boost as CEO by Arlene Weintraub Tuesday, April 11, 2017 Merck & Co.’s CEO Ken Frazier got his first salary bump last year, but the company's troubles caused his total compensation to take a hit.
